Rheumatoid Arthritis Trial, Recruiting NCT06933134 Sponsor: University Hospital, Tours Condition: Rheumatoid Arthritis
Back to Rheumatoid Arthritis

Rheumatoid Arthritis Trial, Recruiting

NCT06933134
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People who have been diagnosed with rheumatoid arthritis based on the 2010 ACR/EULAR classification criteria
  • People who are currently receiving standard-dose rituximab and whose rheumatologist considers them to be responding well to it, and who are being considered for a lower-dose treatment approach
  • People taking certain conventional arthritis medications (such as Methotrexate, Leflunomide, Salazopyrine, or Plaquenil) at a dose that has remained unchanged for at least 3 months
  • People taking corticosteroids (steroid tablets) at a dose of 10 mg per day or less, with that dose remaining stable for at least 3 months

Who may not be able to join:

  • People who are also taking another type of targeted disease-modifying therapy alongside rituximab
  • People who have Sjögren's syndrome or another inflammatory joint or autoimmune condition in addition to rheumatoid arthritis
  • People who have fibromyalgia or another condition that could affect how disease activity is measured
  • People who have an active blood or lymph system disease affecting a type of white blood cell called lymphocytes (such as chronic lymphocytic leukaemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or certain other lymphoma types)
  • People who do not agree to their personal data being used for research purposes
  • People who fall under specific protected legal categories under French public health law, such as minors or adults under legal protection (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 247475917

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Tours
Registry
ClinicalTrials.gov
Start date
23 April 2026
Est. completion
1 November 2028

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Observed Disease Activity Score(DAS) 28-CRP; Calculated DAS28-CRP

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov